Balancing Phase II and III Efficacy Trials

被引：0
|
作者：
Bobby W. Sandage
机构：
[1] Interneuron Pharmaceuticals,
[2] Inc.,undefined
来源：
Drug information journal : DIJ / Drug Information Association | 1998年 / 32卷 / 4期
关键词：
Efficacy trials; Phase II and III;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This paper compares the traditional drug development pathways with an innovative method for combining objectives and study designs within one trial. Evidence is offered in support of combining Phase II and Phase III trials for certain diseases and drugs. Newer regulations and guidelines are encouraging drug developers to be efficient and creative in conducting clinical trials.
引用
收藏
页码：977 / 980
页数：3
相关论文
共 50 条
  • [1] Balancing Phase II and III efficacy trials
    Sandage, BW
    [J]. DRUG INFORMATION JOURNAL, 1998, 32 (04): : 977 - 980
  • [2] The phase II/III transition: Toward the proof of efficacy in cancer clinical trials
    Fazzari, M
    Heller, G
    Scher, HI
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (04): : 360 - 368
  • [3] Efficacy and safety in phase II trials
    Black, DM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (8A): : 25F - 26F
  • [4] Dose selection in seamless phase II/III clinical trials based on efficacy and safety
    Kimani, Peter K.
    Stallard, Nigel
    Hutton, Jane L.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (06) : 917 - 936
  • [5] Phase II/III trials of Viracept start
    不详
    [J]. AIDS PATIENT CARE AND STDS, 1996, 10 (03) : 187 - 187
  • [6] The efficacy of cariprazine in chronic schizophrenia - post hoc analyses of phase II/III clinical trials
    Falkai, P.
    Dombi, Z.
    Acsai, K.
    Barabassy, A.
    Nemeth, G.
    [J]. EUROPEAN PSYCHIATRY, 2022, 65 : S323 - S323
  • [7] Adding dose modifications into Phase II and Phase II/III seamless trials
    Spivack, John
    Cheng, Bin
    Levin, Bruce
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2020, 29 (05) : 1315 - 1324
  • [8] Play the winner for phase II/III clinical trials
    Yao, Q
    Wei, LJ
    [J]. STATISTICS IN MEDICINE, 1996, 15 (21-22) : 2413 - 2423
  • [9] Design Issues in Randomized Phase II/III Trials
    Korn, Edward L.
    Freidlin, Boris
    Abrams, Jeffrey S.
    Halabi, Susan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 667 - 671
  • [10] Tildrakizumab: A Review of Phase II and III Clinical Trials
    Kolli, Sree S.
    Gabros, Sarah D.
    Pona, Adrian
    Cline, Abigail
    Feldman, Steven R.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (04) : 413 - 418
12345